drugset / Trial / NCT02022540

Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD

NCT02022540

Phase 1 Completed 50 enrolled PanOptica, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The objective of this study is to assess the safety and tolerability of topical ocular PAN-90806 in patients with active, subfoveal choroidal neovascularization associated with neovascular Age-Related Macular Degeneration (AMD).

Timeline

Start
2014-02
Primary completion
2016-03
Completion
2016-05

Drugs

EvaluationDrugModalityDoseRoute
Subject OSI-632 Small molecule Topical
Background Ranibizumab Monoclonal antibody Intravitreal